> What counts as an impossible supply challenge is very different at the $500 price point than at the $50 price point.

Considering the insane profits pharmaceutical companies are currently recording, the issue has more to do with these companies favoring their benefits to the detriment of the general population which should come as no surprise to anyone having experience dealing with a pharma company.

The issue is particularly prevalent in Europe because as usual, apart from some grand posturing in the media, Europe will do nothing to fight back.